| US 7,473,696 B2 | ||
| CCR-2 antagonist salt | ||
| Mark Jensen, Holmdel, N.J. (US); Robert Larsen, Bridgewater, N.J. (US); and Daniel Richard Sidler, Whitehouse Station, N.J. (US) | ||
| Assigned to Merck & Co., Inc., Rahway, N.J. (US) | ||
| Appl. No. 10/577,584 PCT Filed Oct. 25, 2004, PCT No. PCT/US2004/035069 § 371(c)(1), (2), (4) Date Apr. 27, 2006, PCT Pub. No. WO2005/044264, PCT Pub. Date May 19, 2005. |
||
| Claims priority of provisional application 60/514735, filed on Oct. 27, 2003. | ||
| Prior Publication US 2007/0135474 A1, Jun. 14, 2007 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 31/4375 (2006.01); C07D 471/04 (2006.01) | ||
| U.S. Cl. 514—300 [546/122] | 2 Claims |
1. The compound:
 |